home > news > detailed info

Sphere Fluidics receives Queen’s Award for Enterprise

Sphere Fluidics

Single cell analysis for therapeutic discovery recognized with prestigious business award for innovation

Cambridge, UK, 21 April 2020: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has be honored with a Queen’s Award for Enterprise for Innovation. The award recognizes the Company’s excellence in patenting, developing and globally commercializing single cell analysis systems for biotherapeutic discovery.

Using its state-of-the-art picodroplet technology, Sphere Fluidics develops and commercializes novel, single cell analysis systems for the rapid screening and characterization of single cells to enable leading edge research and accelerate biopharmaceutical discovery and development. The Company’s flagship product is the multi-award winning, Cyto-Mine® System, which integrates isolation, selective screening, sorting, and imaging into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value cells to be captured in a single run.

Sphere Fluidics spun out from the University of Cambridge in 2010 and now employs 31 people.

Dr. Frank F. Craig, CEO, Sphere Fluidics, said:“We are immensely proud to have our pioneering approach to single cell analysis recognized with a Queen’s Award for Enterprise. This is a testament to the hard work and expertise of our dedicated team who have a deep understanding of the challenges faced by researchers in drug discovery, therapeutics and diagnostics.

Sphere Fluidics’ technology is specifically designed to increase the chances of finding that rare molecule or cell that could lead to a life-changing medicine. Our systems help make the development of new biopharmaceuticals faster and more cost-effective, improve monoclonal antibody screening, cell line development, and overall efficiency to help accelerate research into new therapeutic modalities. Our technology is highly innovative and is covered by 148 international patents and 18 trademarks.”

Sphere Fluidics is one of 220 organizations nationally to be recognized with a prestigious Queen’s Award for Enterprise. Now in its 54th year, the Queen’s Awards for Enterprise are among the most prestigious business awards in the country, with winning businesses able to use the esteemed Queen’s Awards emblem for the next five years.

Sphere Fluidics will be invited to celebrate its award during a royal reception for Queen’s Awards winners in the summer.

For further information about Sphere Fluidics, please visit:

For more information about the Queen’s Award for Enterprise, please visit:
phone +44 1223 804200
email The Jonas Webb Building, Babraham Research Campus, Babraham, Cambridge CB22 3AT, United Kingdom
Print this page
Send to a friend
News and Press Releases

3P Biopharmaceuticals initiates partnership with American Biotech Zhittya for Parkinson’s disease treatment

3P and Zhittya began their relationship at the beginning of 2019 with 3P being selected as the CDMO to transfer the process for scaling up and performing cGMP manufacturing for clinical studies. After successfully achieving transfer of the process, 3P anticipates manufacturing of the first cGMP batch by the second quarter of 2020.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement